Philadelphia, PA, 1 April 2009 – If a drug took the fun out of stealing, would it reduce crime? A new study scheduled for the April 1st issue of Biological Psychiatry, published by Elsevier, suggests that this may be so.
Kleptomania is a type of impulse control disorder characterized by persistent and recurrent patterns of stealing, where afflicted individuals often experience an irresistible urge to steal items they often don't even need. In a rigorous study design, researchers at the University of Minnesota School of Medicine recruited individuals with kleptomania who were actively experiencing urges to steal and randomized them to receive treatment with either naltrexone or placebo. Naltrexone is a drug that blocks the effects of endogenous opiates that may be released during stealing; in other words, it blocks the part of the brain that feels pleasure with certain addictive behaviors. They found that after eight weeks of treatment, naltrexone was able to reduce the urges to steal and stealing behavior in people with kleptomania. Its side effects were generally mild.
Corresponding author Dr. Jon E. Grant further discusses the findings: "These individuals had long histories of stealing, reported urges to steal, and described a 'rush' or thrill from the behavior. Naltrexone's efficacy in treating the symptoms of kleptomania suggests that kleptomania in particular, and impulse control disorders in general, may be related to substance addictions and share a common brain circuitry." Dr. John Krystal, Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, concurs, noting that "this work extends the findings in alcoholism, opiate dependence, smoking, and other addictive disorders where naltrexone has shown evidence of reducing the abuse of substances."
The prevalence rates of kleptomania in the general population are hard to come because these individuals don't usually seek treatment and/or are simply jailed, but billions of dollars worth of items are stolen from retailers every year. That naltrexone appears to be an effective treatment is an important step forward in understanding this disorder and in helping those who suffer from its effects. Further research is now needed to evaluate the long-term effects of naltrexone treatment.
Notes to Editors:
The article is "A Double-Blind, Placebo-Controlled Study of the Opiate Antagonist, Naltrexone, in the Treatment of Kleptomania" by Jon E. Grant, Suck Won Kim, and Brian L. Odlaug. The authors are affiliated with the Department of Psychiatry at the University of Minnesota School of Medicine, Minneapolis, Minnesota. The article appears in Biological Psychiatry, Volume 65, Issue 7 (April 1, 2009), published by Elsevier.
The authors' disclosures of financial and conflicts of interests are available in the article. Dr. Krystal's disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological_Psychiatry_Editorial_Disclosures_08_01_08.pdf.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at ja.dawkins@elsevier.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry (www.sobp.org/journal) is ranked 4th out of the 95 Psychiatry titles and 16th out of 199 Neurosciences titles on the 2006 ISI Journal Citations Reports® published by Thomson Scientific.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Journal
Biological Psychiatry